Drug Profile
Levocetirizine/Montelukast - Qrono
Alternative Names: QR 215Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Qrono
- Class Acetates; Antiallergics; Antiasthmatics; Nonsedating antihistamines; Piperazines; Quinolines; Quinolones
- Mechanism of Action Histamine H1 receptor antagonists; Leukotriene D4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for research development in Unspecified in USA (Parenteral, Injection)
- 16 Aug 2017 Chemical structure information added
- 04 Aug 2017 Levocetirizine/Montelukast- Qrono is available for licensing as of 04 Aug 2017. http://qrono.com/pipeline/ (Qrono pipeline, August 2017)